Sight Sciences: Signs Of Progress, But Plenty Of Work Remains

Sight Sciences’ Q2 revenue grew 20%, with accelerating dry eye business, improved gross margins and reduced cash burn; Aetna coverage adds 25 million insured lives to its glaucoma business. The OMNI Ultra launch and updated TearCare label offer incremental adoption tailwinds, but liquidity pressure, reimbursement and procedure-cost challenges, and surgeon preferences remain hurdles.

Analysis

The key underwriting question is conversion, not coverage: additional covered lives have little near-term value unless eligible patients are identified, claims are paid consistently, and surgeons find the procedure economically worthwhile. Coverage expansion could improve referral confidence over the next 1–3 months, but utilization and repeatable reimbursement evidence are more informative than the covered-lives headline. OMNI Ultra and the revised TearCare label may broaden adoption, though launches can raise commercial costs before volume meaningfully offsets them. If surgeons remain reluctant or payer rules constrain use, competing glaucoma and dry-eye treatment providers—including Glaukos in glaucoma—could capture demand without SGHT realizing the expected operating leverage.

Over 6–18 months, improving gross margins and lower cash burn would strengthen the case that growth can fund the commercial push; persistent liquidity pressure raises dilution or financing risk. The contrarian risk is that investors may overvalue payer access and product momentum before utilization is demonstrated. Conversely, if procedure volume and cash conversion improve together, the market may underappreciate the durability of adoption. Falsifiers: reimbursement denials or restrictive policy changes, weak procedure growth, renewed cash-burn deterioration, or management reducing growth expectations.

Key Decisions for Investors

• Treat SGHT as a conditional, small-size long rather than chase the reimbursement headline; add only after evidence that coverage is translating into paid procedures and utilization, not merely eligible lives.
• For the next 1–3 months, monitor procedure volumes, payer-policy details, gross-margin progression, and cash burn. Verify liquidity/runway from filings before sizing; the article does not provide enough information to quantify financing risk.
• Keep Glaukos and other relevant procedure providers on the relative watchlist: SGHT adoption shortfalls could redirect demand, but do not establish a pair trade without comparative valuation and procedure-growth data.
• Reduce or exit the thesis if utilization stalls, reimbursement access narrows, cash burn reverses materially, or guidance weakens; reconsider adding if paid utilization and margin improvement persist over multiple reporting periods.